Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "AIM"

1747 News Found

Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay
Drug Approval | November 30, 2025

Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay

The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026


Exyte completes Pharmaplan integration
Biopharma | November 28, 2025

Exyte completes Pharmaplan integration

Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division


Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies
R&D | November 28, 2025

Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies

GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030


Philips’ next-gen platform lets radiologists work anywhere, faster
Digitisation | November 27, 2025

Philips’ next-gen platform lets radiologists work anywhere, faster

The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time


Transmural Systems wins breakthrough FDA nod for coronary-saving TAVR device
Medical Device | November 27, 2025

Transmural Systems wins breakthrough FDA nod for coronary-saving TAVR device

The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions


Gavi and UNICEF ink agreement to slash malaria vaccine price
Healthcare | November 27, 2025

Gavi and UNICEF ink agreement to slash malaria vaccine price

The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses


Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
Clinical Trials | November 26, 2025

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks